Source comparison
CJC-1295 vs IGF-1 LR3: Research Protocol Comparison
Mechanism of Action GHRH receptor agonist → amplifies pituitary GH pulses Direct IGF-1 receptor agonist → bypasses pituitary CJC-1295 requires intact pituitary function; IGF-1 LR3 does not. Half-Life 6–8 days 20–30 hours CJC-1295's extended half-life allows we
This comparison does not assign a generated winner or score.
- Mechanism of Action
- GHRH receptor agonist → amplifies pituitary GH pulses
- Direct IGF-1 receptor agonist → bypasses pituitary
- CJC-1295 requires intact pituitary function; IGF-1 LR3 does not.
- Half-Life
- 6–8 days
- 20–30 hours
- CJC-1295's extended half-life allows weekly dosing but limits mid-protocol adjustments.
- Typical Research Dose
- 1–2 mg per week (subcutaneous)
- 20–100 mcg per day (subcutaneous or intramuscular)
- IGF-1 LR3 requires daily administration; CJC-1295 maintains stable plasma levels with 1–2 weekly doses.
- Primary Signaling Pathway
- cAMP → PKA → GH secretion → hepatic IGF-1 production
- PI3K/Akt → mTOR → protein synthesis and glucose uptake
- CJC-1295 works upstream (pituitary); IGF-1 LR3 works downstream (tissue receptors).
- Feedback Inhibition
- Yes. Elevated IGF-1 suppresses further GHRH release
- No. Bypasses hypothalamic-pituitary feedback loop
- CJC-1295 self-regulates; IGF-1 LR3 does not, requiring external dosing control to prevent receptor saturation.
- Washout Period
- 3–4 weeks
- 5–7 days
- IGF-1 LR3 clears faster, allowing quicker protocol modifications or cessation.
- Hypoglycemia Risk
- Low. GH is counter-regulatory (raises blood glucose)
- Moderate. IGF-1 LR3 binds insulin receptors with ~10% affinity
- Protocols using IGF-1 LR3 should monitor glucose levels, especially in fasted states or high-dose studies.
- Optimal Research Context
- Models examining GH pulse restoration, sleep-related GH secretion, metabolic dysfunction with intact pituitary
- Models examining direct anabolic signaling, GH-resistant states, localized tissue repair, insulin-IGF-1 crosstalk
- Use CJC-1295 when the goal is restoring physiological GH patterns; use IGF-1 LR3 when bypassing the pituitary is necessary or desirable.